NCT00694720

Evaluation of the Effect of AVE0657 in Cheynes-Stokes Breathing Syndrome Patients

A Double-Blind, Randomized, Placebo-Controlled, Study Evaluating the Safety and Activity of Four Escalating Single Doses of AVE0657 in Congestive Heart Failure Patients Presenting as Cheyne-Stokes Breathing Syndrome

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Sanofi · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to assess the activity on breathing parameters of 4 escalating doses of AVE0657 in comparison to placebo in patients with Cheynes-Stokes Breathing Syndrome.

Conditions

• Heart Failure
• Sleep Apnea Syndromes
• Cheyne-Stokes Respiration

Interventions

Type	Name	Description
DRUG	AVE0657	capsules once a day at bedtime
DRUG	placebo	capsules once a day at bedtime

Timeline

• Start date: 2008-06-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2008-06-10
• Last updated: 2009-05-01

Locations

3 sites across 3 countries: France, Germany, Spain